{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-009752","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2021-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.784249+00:00","generated_at":"2026-06-29T23:43:24.572381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TG Therapeutics Q2 net loss $78.5M; UKONIQ revenue $1.5M; U2 PDUFA March 2022","bullets":["Net loss $78.5M for Q2 2021, up from $52.9M in Q2 2020; ex-stock comp net loss ~$62.2M.","UKONIQ net revenue $1.5M in Q2 (total $2.3M since Feb 2021 launch); product revenue zero year ago.","FDA accepted BLA/sNDA for U2 (ublituximab+UKONIQ) in CLL/SLL; PDUFA goal date March 25, 2022.","Cash $456.2M at June 30, 2021; company expects to fund operations into 2023.","Plan to submit BLA for ublituximab in relapsing MS in Q3 2021 based on positive Phase 3 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-009752","json":"https://secwatch.observer/filing/0001558370-21-009752.json","markdown":"https://secwatch.observer/filing/0001558370-21-009752.md","text":"https://secwatch.observer/filing/0001558370-21-009752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/0001558370-21-009752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837021009752/tgtx-20210802x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:43:24.572381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}